Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

464 public trials 49 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

NCT01051817

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +7 more
Locations
  • Novartis Investigative Site Hradec Králové, Czech Republic, Czechia
  • Novartis Investigative Site Ostrava, Czechia
  • Novartis Investigative Site Ostrava-Moravska Ostrava, Czechia
  • Novartis Investigative Site Prague, Czechia
View all 16 locations
View Trial Details
Completed

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01097668

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Municipal Healthcare Institution "City Clinical Hospital #3", Department of neurology Chelyabinsk, Russia
  • State Medical Institution "Republican Clinical Hospital of rehabilitation treatment of Ministry of Healthcare of Tatarstan Republic", Republican clinicodiagnostic center of demyelinating diseases of Ministry of Healthcare of Tatarstan Republic Kazan', Russia
  • State Educational Institution of Higher Professional Education "1st Moscow State Medical University n.a. I.M. Sechenov of Ministry of Healthcare and Social Development of the Russian Federation, Department of new drugs research Moscow, Russia
  • State Healthcare Institution 'Rostov Regional Clinical Hospital' Center of Neurology Rostov-on-Don, Russia
View all 16 locations
View Trial Details
Completed

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +10 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Cullman, Alabama, United States
  • Research Site Huntsville, Alabama, United States
  • Research Site Phoenix, Arizona, United States
View all 195 locations
View Trial Details
Completed

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

NCT00420212

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +10 more
Locations
  • Research Site Gilbert, Arizona, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site San Francisco, California, United States
  • Research Site New Haven, Connecticut, United States
View all 159 locations
View Trial Details
Completed

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

NCT00050778

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Mayo Clinic Scottsdale Arizona Scottsdale, Arizona, United States
  • Clinical Trials, Inc Little Rock, Arkansas, United States
  • East Bay Physicians Medical Group Berkeley, California, United States
  • Nerve Pro Research Irvine, California, United States
View all 49 locations
View Trial Details
Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

NCT00530348

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • North Central Neurology Associates, P.C. Cullman, Alabama, United States
  • Barrow Neurological Institute, St. Joseph's Hospital & Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • Northwest NeuroSpecialists, PLLC Tucson, Arizona, United States
View all 101 locations
View Trial Details
Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

NCT00559702

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +12 more
Locations
  • Research Site Phoenix, Arizona, United States
  • Research Site Scottsdale, Arizona, United States
  • Research Site Berkeley, California, United States
  • Research Site Centennial, Colorado, United States
View Trial Details

Related conditions